• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

The Biosimilar Hadlima Launches with a Price That is 85% off Humira


A carton of Hadlima including two pre-filled pens or two pre-filled syringes is available at a list price of $1,038.

Organon and Samsung Bioepis have launched the biosimilar Hadlima, (adalimumab-bwwd) with list price that is an 85% discount off the reference product Humira. Hadlima is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL). A carton including two pre-filled pens or two pre-filled syringes is available at a list price of $1,038. Organon is also offering a copay support program for as little as $0 copay, as well as a patient assistance program and dedicated nurse coaches.

Hadlima is a tumor necrosis factor (TNF) blocker indicated for appropriate patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. Hadlima’s PushTouch autoinjector was designed with a thin 29G needle, a latex-free needle cover, and a buttonless device with a sure-grip shape and a non-slip surface. The autoinjector has been awarded the Arthritis Foundation’s Ease of Use Certification.

“As the largest loss-of-exclusivity event in pharmaceutical history, this is a singular moment for the U.S. healthcare system to embrace biosimilars. Every stakeholder should be invested in the success of this market to realize the value biosimilars can create for patients, providers, and the U.S. healthcare economy,” Kevin Ali, chief executive officer of Organon, said in a press release.

Samsung Bioepis’s adalimumab biosimilar (marketed under different brand names outside of the United States) has been available in 24 markets globally since 2018.

Hadlima is the third Humira biosimilar, so far, to provide pricing information this year. Amgen’s Amjevita launched in January with two pricing options, and last month, Coherus BioScience announced that it would provide Yusimry with a list price of $995 per carton. Other Humira biosimilars expected to launch this month include Fresenius Kabi’s Idacio, Viatris’ Hulio, and Sandoz’ Hyrimoz.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.